Human Neuropilin‑1 Antibody

1 citations
  • Specificity
    Detects human Neuropilin-1 in direct ELISAs.
  • Source
    Monoclonal Mouse IgG2A Clone # 446921
  • Purification
    Protein A or G purified from hybridoma culture supernatant
  • Immunogen
    Mouse myeloma cell line NS0-derived recombinant human Neuropilin‑1
    Accession # NP_001019799
  • Formulation
    Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
  • Label
  • Flow Cytometry
    2.5 µg/106 cells
    See below
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Data Examples
Detection of Neuropilin‑1 in HUVEC Human Cells by Flow Cytometry. HUVEC human umbilical vein endothelial cells were stained with Human Neuropilin‑1 Monoclonal Antibody (Catalog # MAB3870, filled histogram) or isotype control antibody (Catalog # MAB003, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG
F(ab')2 Secondary Antibody (Catalog # F0102B).
Preparation and Storage
  • Reconstitution
    Reconstitute at 0.5 mg/mL in sterile PBS.
  • Shipping
    The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
  • Stability & Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 12 months from date of receipt, -20 to -70 °C as supplied.
    • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
    • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Neuropilin-1

Neuropilin-1 (Npn-1, previously neuropilin; also CD304) is a 130‑140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis (1‑4). The full-length 923 amino acid (aa) human Npn‑1 contains a 623 aa extracellular domain (ECD) that shows 92‑95% aa identity with mouse, rat, bovine and canine Npn‑1 (3, 4). The ECD contains two N-terminal CUB domains (termed a1a2), two domains with homology to coagulation factors V and VIII (b1b2) and a MAM (meprin) domain (c). C-terminally divergent splice variants with 704, 644, 609, and 551 aa lack the MAM and TM domains and are demonstrated or presumed to be soluble antagonists (1, 5‑7). A 906 aa form lacks a TM segment, but secretion has not been found (8). The sema domains of Class III secreted semaphorins such as Sema3A bind Npn-1 a1a2 (9). Heparin, the heparin-binding forms of VEGF (VEGF165, VEGF-B and VEGF-E), PlGF (PlGF2), and the C-terminus of Sema3 bind the b1b2 region (9, 10). Npn-1 and Npn-2 share 48% aa identity within the ECD and can form homo- and hetero-oligomers via interaction of their MAM domains (1). Neuropilins show partially overlapping expression in neuronal and endothelial cells during development (1, 2). Both neuropilins act as co‑receptors with plexins, mainly plexin A3 and A4, to bind class III semaphorins that mediate axon repulsion (11). However, only Npn-1 binds Sema3A, and only Npn-2 binds Sema3F (1). Both are co-receptors with VEGF R2 (also called KDR or Flk-1) for VEGF165 binding (1). Sema3A signaling can be blocked by VEGF165, which has higher affinity for Npn-1 (12). Npn-1 is preferentially expressed in arteries during development or those undergoing remodeling (1, 2). Npn-1 is also expressed on dendritic cells and mediates DC-induced T cell proliferation (13).

  • References:
    1. Bielenberg, D.R. et al. (2006) Exp. Cell Res. 312:584. 
    2. Gu, C. et al. (2003) Dev. Cell 5:45. 
    3. He, Z. and M. Tessier-Lavigne (1997) Cell 90:739.
    4. Soker, S. et al. (1998) Cell 92:735. 
    5. Gagnon, M.L. et al. (2000) Proc. Natl. Acad. Sci. USA 97:2573. 
    6. Cackowski, F.C. et al. (2004) Genomics 84:82. 
    7. Rossignol, M. et al. (2000) Genomics 70:211.
    8. Tao, Q. et al. (2003) Angiogenesis 6:39.
    9. Gu, C. et al. (2002) J. Biol. Chem. 277:18069.
    10. Mamluk, R. et al. (2002) J. Biol. Chem. 277:24818.
    11. Yaron, A. et al. (2005) Neuron 45:513.
    12. Narazaki, M. and G. Tosato (2006) Blood 107:3892.
    13. Tordjman, R. et al. (2002) Nat. Immunol. 3477.
  • Alternate Names:
    BDCA-4; CD304; NRP1; BDCA4; CD304 antigen; DKFZp686A03134; DKFZp781F1414; neuropilin 1; neuropilin-1; NRPNP1; transmembrane receptor; Vascular endothelial cell growth factor 165 receptor; VEGF165RCD304
Related Research Areas

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

Showing Results 1 - 1 of 1

  1. The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1.
    Authors: Jaalouk DE, Ozawa MG, Sun J, Lahdenranta J, Schlingemann RO, Pasqualini R, Arap W
    Cancer Res., 2007;67(20):9623-9.
    Species: Mouse
    Sample Type: NRP-1 Protein
    Application: Neutralization,


No product specific FAQs exist for this product, however you may click here to view all FAQs for Primary Antibodies

Order Details

Contact Information

Certificate of Analysis Lookup

The document you requested is not available online. Please enter the Catalog Number and Lot Number below to have a document emailed to you at the address provided

Certificate of Analysis Lookup

Research Areas of Interest


Customer Information